vs
NewtekOne, Inc.（NEWT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是NewtekOne, Inc.的1.7倍（$127.1M vs $73.3M），再鼎医药同比增速更快（17.1% vs -2.7%），再鼎医药自由现金流更多（$-26.7M vs $-579.3M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.2%）
纽泰克是一家总部位于美国得克萨斯州圣安东尼奥的软硬件企业，专注于为个人电脑提供直播、后期制作视频工具及视觉成像软件。公司由蒂姆·杰尼森与保罗·蒙哥马利于1985年在美国堪萨斯州托皮卡创立，2019年4月宣布被Vizrt收购。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
NEWT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$73.3M
营收增速更快
ZLAB
高出19.8%
-2.7%
自由现金流更多
ZLAB
多$552.6M
$-579.3M
两年增速更快
ZLAB
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.3M | $127.1M |
| 净利润 | $19.5M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 111.8% | — |
| 营收同比 | -2.7% | 17.1% |
| 净利润同比 | 6.6% | — |
| 每股收益（稀释后） | $0.64 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEWTZLAB
| Q4 25 | $73.3M | $127.1M | ||
| Q3 25 | $74.9M | $115.4M | ||
| Q2 25 | $70.2M | $109.1M | ||
| Q1 25 | $66.3M | $105.7M | ||
| Q4 24 | $75.4M | $108.5M | ||
| Q3 24 | $62.8M | $101.8M | ||
| Q2 24 | $61.1M | $100.1M | ||
| Q1 24 | $58.3M | $87.1M |
净利润NEWTZLAB
| Q4 25 | $19.5M | — | ||
| Q3 25 | $17.9M | $-36.0M | ||
| Q2 25 | $13.7M | $-40.7M | ||
| Q1 25 | $9.4M | $-48.4M | ||
| Q4 24 | $18.3M | — | ||
| Q3 24 | $11.9M | $-41.7M | ||
| Q2 24 | $10.9M | $-80.3M | ||
| Q1 24 | $9.7M | $-53.5M |
毛利率NEWTZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率NEWTZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% | ||
| Q1 24 | — | -80.7% |
净利率NEWTZLAB
| Q4 25 | 111.8% | — | ||
| Q3 25 | 23.9% | -31.2% | ||
| Q2 25 | 19.5% | -37.3% | ||
| Q1 25 | 14.1% | -45.8% | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 19.0% | -40.9% | ||
| Q2 24 | 17.9% | -80.2% | ||
| Q1 24 | 16.6% | -61.4% |
每股收益（稀释后）NEWTZLAB
| Q4 25 | $0.64 | $-0.05 | ||
| Q3 25 | $0.67 | $-0.03 | ||
| Q2 25 | $0.52 | $-0.04 | ||
| Q1 25 | $0.35 | $-0.04 | ||
| Q4 24 | $0.70 | $-0.09 | ||
| Q3 24 | $0.45 | $-0.04 | ||
| Q2 24 | $0.43 | $-0.08 | ||
| Q1 24 | $0.38 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $819.9M | — |
| 股东权益账面价值 | $397.6M | $715.5M |
| 总资产 | $2.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 2.06× | — |
8季度趋势，按日历期对齐
现金及短期投资NEWTZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务NEWTZLAB
| Q4 25 | $819.9M | — | ||
| Q3 25 | $748.5M | — | ||
| Q2 25 | $657.3M | — | ||
| Q1 25 | $774.0M | — | ||
| Q4 24 | $708.0M | — | ||
| Q3 24 | $655.8M | — | ||
| Q2 24 | $652.0M | — | ||
| Q1 24 | $662.5M | — |
股东权益NEWTZLAB
| Q4 25 | $397.6M | $715.5M | ||
| Q3 25 | $386.7M | $759.9M | ||
| Q2 25 | $312.2M | $791.7M | ||
| Q1 25 | $302.3M | $810.8M | ||
| Q4 24 | $296.3M | $840.9M | ||
| Q3 24 | $281.8M | $667.7M | ||
| Q2 24 | $274.0M | $704.2M | ||
| Q1 24 | $254.1M | $762.2M |
总资产NEWTZLAB
| Q4 25 | $2.7B | $1.2B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.1B | $1.2B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $1.7B | $985.3M | ||
| Q2 24 | $1.6B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
负债/权益比NEWTZLAB
| Q4 25 | 2.06× | — | ||
| Q3 25 | 1.94× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.33× | — | ||
| Q2 24 | 2.38× | — | ||
| Q1 24 | 2.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-579.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-579.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | -790.0% | -21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | -29.64× | — |
| 过去12个月自由现金流最近4个季度 | $-1.0B | $-158.9M |
8季度趋势，按日历期对齐
经营现金流NEWTZLAB
| Q4 25 | $-579.2M | $-26.0M | ||
| Q3 25 | $-167.3M | $-32.0M | ||
| Q2 25 | $-199.8M | $-31.0M | ||
| Q1 25 | $-60.7M | $-61.7M | ||
| Q4 24 | $-153.0M | $-55.8M | ||
| Q3 24 | $-25.7M | $-26.8M | ||
| Q2 24 | $2.9M | $-42.2M | ||
| Q1 24 | $-38.7M | $-90.1M |
自由现金流NEWTZLAB
| Q4 25 | $-579.3M | $-26.7M | ||
| Q3 25 | $-167.3M | $-35.0M | ||
| Q2 25 | $-199.9M | $-33.9M | ||
| Q1 25 | $-60.7M | $-63.2M | ||
| Q4 24 | $-153.5M | $-58.4M | ||
| Q3 24 | $-25.9M | $-28.2M | ||
| Q2 24 | $2.9M | $-42.9M | ||
| Q1 24 | $-38.7M | $-91.1M |
自由现金流率NEWTZLAB
| Q4 25 | -790.0% | -21.0% | ||
| Q3 25 | -223.3% | -30.4% | ||
| Q2 25 | -284.7% | -31.1% | ||
| Q1 25 | -91.6% | -59.9% | ||
| Q4 24 | -203.6% | -53.8% | ||
| Q3 24 | -41.2% | -27.7% | ||
| Q2 24 | 4.7% | -42.9% | ||
| Q1 24 | -66.5% | -104.5% |
资本支出强度NEWTZLAB
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.6% | 2.4% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
现金转化率NEWTZLAB
| Q4 25 | -29.64× | — | ||
| Q3 25 | -9.35× | — | ||
| Q2 25 | -14.58× | — | ||
| Q1 25 | -6.48× | — | ||
| Q4 24 | -8.35× | — | ||
| Q3 24 | -2.15× | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | -4.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEWT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
